The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections
LYS228 Pharmacokinetics for Complicated UTI
A Randomized, Controlled, Evaluator-blinded, Multi-center, study to evaluate LYS228 pharmacokinetics, clinical response, safety and tolerability in patients with complicated urinary tract infection
Urinary tract infections
All genders
18-85
Recruiting now
Overview
Principal Investigator: Dr. Yoav Golan
Contact Us
Deirdre Burke
Study details
Inclusion Criteria
- Male and female patients 18 to 85 years of age
- Suspected and/or bacteriologically documented complicated UTI judges by the investigator to be serious (required patient to be hospitalized for treatment with intravenous antibiotics)
Exclusion Criteria
- Prior antibiotics within the past 72 hours
- Urine culture resulting with fungal UTI colony count of more than 130 CFU/mL
- Urine culture resulting in more than 2 different species of microorganisms, or if a gram positive organism is present with >= 105 CFU/mL count.
Study Requirements
Blood draw, Urine samples, clinic visits